Epstein Secrets

Dengue virus, and Yellow fever virus). (Kindly see belo= abstract of manuscript just being submitted). In addition, in collaboration with Professor Soper at UNC, we have been building =icro-fabricated devices to rapidly detect pathogens. Most recently, we have begun designing micro-fabricated devices

evices suitable f=r working in developing countries, and may be powered and run by a cell phone or smart device. • Current CDC approved EZ1-RT-P=R Taqman assay has LOD of 5,000 PFU/ml. This works when patient is&nbs=;febrile, i.e. has overt symptoms and may be contagious. • Next level of assay needs

Dengue virus, and Yellow fever virus). (Kindly see b=low abstract of manuscript just being submitted). In addition, =n collaboration with Professor Soper at UNC, we have been building4) micro-fabricated devices to rapidly detect pathogens. Most recently, we have begun designing micro-fabricated devic

ricated devices that w=ll allow for electronic detection, obviating the need for expens=ve hardware used in most fluorescent detection schemes (i.e. Taqman a=says). As such, we are poised to combine these technologie= for rapidly identifying and providing quantitative viral load fo= all the VHF, Variol

Dengue virus, and Yellow fever virus). (Kindly see belo= abstract of manuscript just being submitted). In addition, in collaboration with Professor Soper at UNC, we have been building =icro-fabricated devices to rapidly detect pathogens. Most recently, we have begun designing micro-fabricated devices

devices suitable f=r working in developing countries, and may be powered and run by a cell phone or smart device. • Current CDC approved EZ1-RT-P=R Taqman assay has LOD of 5,000 PFU/ml. This works when patient is&nbs=;febrile, i.e. has overt symptoms and may be contagious. • Next level of assay needs